In urothelial carcinomas, FGFR3 was able to induce a proangiogenic phenotype, suggesting that constitutive activation of FGFR3 may be able to potentiate growth factor signalling in the tumour microenvironment and implicating FGFR3 as a potential therapeutic target from an antiangiogenic perspective [87]. Here, FGFR3 is linked to neoplasm.